Den centraliserede procedure er obligatorisk for bioteknologisk fremstillede lægemidler og kan anvendes for andre innovative produkter efter virksomhedens anmodning.
The decentralised procedure (or mutual recognition procedure) applies to the majority of conventional medicinal products and is based upon the principle of mutual recognition of national authorisations.